-
STANDARDIZING AN ANNUAL REFERENCE COMPARATOR OF HEALTHCARE UTILIZATION OF PAINFUL DIABETIC NEUROPATHY (PDPN): A U.S. CLAIMS COHORT META-ANALYSIS FOR MODELING AND PAYER BENCHMARKING
Mar 18, 2026, 21:38 PM -
VALUE SETS FOR AQOL, EQ-5D, HUI, QWB AND SF-6D: A SYSTEMATIC REVIEW OF THEIR AVAILABILITY AND CHARACTERISTICS
Mar 18, 2026, 21:38 PM -
PRICE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION
Mar 18, 2026, 21:38 PM -
COMPARATIVE RISK OF SUICIDAL IDEATION AND SELF-HARM AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH BREXPIPRAZOLE VERSUS OTHER ORAL ATYPICAL ANTIPSYCHOTICS: A PROPENSITY SCORE-MATCHED COHORT ANALYSIS
Mar 18, 2026, 21:38 PM -
GLOBAL AVAILABILITY AND ACCESS TO EVIDENCE-BASED ANTI-OBESITY PHARMACOTHERAPIES: A SYSTEMATIC ASSESSMENT OF REGULATORY AND REIMBURSEMENT LANDSCAPES
Mar 18, 2026, 21:38 PM -
BREAST CANCER PATTERNS AND TREATMENT ACCESS IN DENMARK: IDENTIFYING OPPORTUNITIES FOR DECENTRALIZED CARE IN BREAST CANCER CARE (HEATMAP-ONKO-BREAST)
Mar 18, 2026, 21:38 PM -
THE DIABETES PENALTY, ARE WE COMPARING LIKE VERSUS LIKE IN OBESITY MANAGEMENT? RE-RANKING SEMAGLUTIDE AND TIRZEPATIDE AFTER ADJUSTING FOR COMORBID T2D CONFOUNDING
Mar 18, 2026, 21:38 PM -
ASSESSING ACCESS TO INNOVATIVE ORPHAN MEDICINES IN LATIN AMERICA: A CROSS-COUNTRY VALUE AND ACCESS ANALYSIS
Mar 18, 2026, 21:38 PM -
DIGITAL CAREGIVER TRAINING FOR PROMOTING FUNCTIONAL INDEPENDENCE AND HEALTHY AGING
Mar 18, 2026, 21:38 PM -
AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Mar 18, 2026, 21:38 PM -
AN AI-BASED MODEL EXPLAINER TO SUPPORT ONBOARDING AND KNOWLEDGE TRANSFER FOR EXCEL COST-EFFECTIVENESS MODELS
Mar 18, 2026, 21:38 PM -
ASSESSING THE IMPACT OF INCLUSION OF PATIENTS WITH MISSING EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS IN REAL-WORLD OUTCOMES OF THIRD-LINE OR LATER (3L+) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PRECISION SCREENING FOR ATRIAL FIBRILLATION: A DECISION-ANALYTIC MODEL
Mar 18, 2026, 21:38 PM -
REAL-WORLD DIAGNOSTIC DELAY, TREATMENT ACCESS, AND HEALTH SYSTEM BURDEN IN PRIMARY IMMUNODEFICIENCY/INBORN ERRORS OF IMMUNITY: EVIDENCE FROM THE UNITED STATES AND EX-US SETTINGS
Mar 18, 2026, 21:38 PM -
SYSTEMATIC REVIEW OF HEALTH ECONOMIC EVALUATIONS OF RARE DISEASES IN MEXICO
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF SOCIAL DETERMINANTS OF HEALTH WITH RARE CANCER BURDEN IN THE UNITED STATES: A MEPS-BASED ANALYSIS
Mar 18, 2026, 21:38 PM -
A REAL-WORLD US COMMUNITY-BASED EVALUATION OF RECURRENCE AMONG INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Mar 18, 2026, 21:38 PM -
BURDEN OF LUPUS NEPHRITIS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE: A REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM -
COST-SAVINGS ASSOCIATED WITH VENETOCLAX-OBINUTUZUMAB VERSUS COVALENT BRUTON’S TYROSINE KINASE INHIBITOR IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM
